| Monica M Brewster, APRN, CRNA | |
|
326 Washington Street, Norwich, CT 06360 | |
| (860) 889-8331 | |
| Not Available |
| Full Name | Monica M Brewster |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 26 Years |
| Location | 326 Washington Street, Norwich, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922135250 | NPI | - | NPPES |
| 1922135250 | Medicaid | CT | |
| 004213089 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 002106 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| William W Backus Hospital | Norwich, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North American Partners In Anesthesia Connecticut Pc | 6709877939 | 45 |
News Archive
Sen. Jim DeMint (R-S.C.) plans to place a hold on President Bush's nomination of acting FDA Commissioner Andrew von Eschenbach to permanently head the agency unless "immediate steps" are taken to remove Danco Laboratories' medical abortion drug Mifeprex from the market, DeMint press secretary Wesley Denton said recently, the New York Times reports.
Breastfeeding for at least six months might lower the risk of developing so-called "triple negative" breast cancer, an aggressive form of the disease that is more common in black and younger women, according to a study published on Monday in the journal Cancer, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 8/24).
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
Also in the news, media outlets report on a range of issues related to the health law's implementation, including accountable care organizations, essential benefits and an HHS warning about a fake website related to the measure's pre-existing condition insurance plan.
› Verified 6 days ago
| Entity Name | Integrated Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881636397 PECOS PAC ID: 1759281165 Enrollment ID: O20040112000163 |
News Archive
Sen. Jim DeMint (R-S.C.) plans to place a hold on President Bush's nomination of acting FDA Commissioner Andrew von Eschenbach to permanently head the agency unless "immediate steps" are taken to remove Danco Laboratories' medical abortion drug Mifeprex from the market, DeMint press secretary Wesley Denton said recently, the New York Times reports.
Breastfeeding for at least six months might lower the risk of developing so-called "triple negative" breast cancer, an aggressive form of the disease that is more common in black and younger women, according to a study published on Monday in the journal Cancer, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 8/24).
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
Also in the news, media outlets report on a range of issues related to the health law's implementation, including accountable care organizations, essential benefits and an HHS warning about a fake website related to the measure's pre-existing condition insurance plan.
› Verified 6 days ago
| Entity Name | North American Partners In Anesthesia Connecticut Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316994775 PECOS PAC ID: 6709877939 Enrollment ID: O20040519000120 |
News Archive
Sen. Jim DeMint (R-S.C.) plans to place a hold on President Bush's nomination of acting FDA Commissioner Andrew von Eschenbach to permanently head the agency unless "immediate steps" are taken to remove Danco Laboratories' medical abortion drug Mifeprex from the market, DeMint press secretary Wesley Denton said recently, the New York Times reports.
Breastfeeding for at least six months might lower the risk of developing so-called "triple negative" breast cancer, an aggressive form of the disease that is more common in black and younger women, according to a study published on Monday in the journal Cancer, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 8/24).
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
Also in the news, media outlets report on a range of issues related to the health law's implementation, including accountable care organizations, essential benefits and an HHS warning about a fake website related to the measure's pre-existing condition insurance plan.
› Verified 6 days ago
| Entity Name | Connecticut Gi Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023124625 PECOS PAC ID: 9830110758 Enrollment ID: O20070112000011 |
News Archive
Sen. Jim DeMint (R-S.C.) plans to place a hold on President Bush's nomination of acting FDA Commissioner Andrew von Eschenbach to permanently head the agency unless "immediate steps" are taken to remove Danco Laboratories' medical abortion drug Mifeprex from the market, DeMint press secretary Wesley Denton said recently, the New York Times reports.
Breastfeeding for at least six months might lower the risk of developing so-called "triple negative" breast cancer, an aggressive form of the disease that is more common in black and younger women, according to a study published on Monday in the journal Cancer, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 8/24).
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
Also in the news, media outlets report on a range of issues related to the health law's implementation, including accountable care organizations, essential benefits and an HHS warning about a fake website related to the measure's pre-existing condition insurance plan.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Monica M Brewster, APRN, CRNA 3998 Fair Ridge Dr.,, Suite 300 Att Credentialing, Fairfax,, VA 22033-2921 Ph: (703) 295-9360 | Monica M Brewster, APRN, CRNA 326 Washington Street, Norwich, CT 06360 Ph: (860) 889-8331 |
News Archive
Sen. Jim DeMint (R-S.C.) plans to place a hold on President Bush's nomination of acting FDA Commissioner Andrew von Eschenbach to permanently head the agency unless "immediate steps" are taken to remove Danco Laboratories' medical abortion drug Mifeprex from the market, DeMint press secretary Wesley Denton said recently, the New York Times reports.
Breastfeeding for at least six months might lower the risk of developing so-called "triple negative" breast cancer, an aggressive form of the disease that is more common in black and younger women, according to a study published on Monday in the journal Cancer, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 8/24).
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
Also in the news, media outlets report on a range of issues related to the health law's implementation, including accountable care organizations, essential benefits and an HHS warning about a fake website related to the measure's pre-existing condition insurance plan.
› Verified 6 days ago
Abigail Conner, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 326 Washington St, Norwich, CT 06360 Phone: 203-929-7353 Fax: 203-929-0756 | |
Brynne E Radel, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 326 Washington St, Norwich, CT 06360 Phone: 860-933-6903 | |
Sandra C Jeppesen, APRN, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 326 Washington St, Norwich, CT 06360 Phone: 860-889-8331 | |
Mary Ellen Comolli, APRN, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 326 Washington St, Norwich, CT 06360 Phone: 860-889-8331 | |
Ms. Lois Caldrello, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 326 Washington St, Dept Of Anesthesia, Norwich, CT 06360 Phone: 860-889-8331 | |
Kalie Morrissette, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 326 Washington St, Norwich, CT 06360 Phone: 860-889-8331 | |
Ms. Bertha M Doss, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 326 Washington St, Anesthesia Department, Norwich, CT 06360 Phone: 860-826-6395 Fax: 860-823-6563 |